%PDF-1.4
%
35 0 obj
<>
endobj
32 0 obj
<>
endobj
124 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-03T10:44:26Z
2024-03-29T00:41:05-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T00:41:05-07:00
application/pdf
Heather
2001-375
uuid:a7057a26-1dd1-11b2-0a00-7809275dc400
uuid:a7057a28-1dd1-11b2-0a00-810000000000
endstream
endobj
21 0 obj
<>
endobj
22 0 obj
<>
endobj
36 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
140 0 obj
[145 0 R]
endobj
141 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.0816 Tw 10 0 0 10 54 713.1616 Tm
(play an important role in the occurrence of pain in FM. In)Tj
0.0461 Tw 0 -1.2 TD
(addition, our results do not support the correlation between)Tj
0.0004 Tc 0.3746 Tw T*
(depression level and serum cytokines in patients with)Tj
0 Tc 0 Tw T*
(fibromyalgia.)Tj
/TT1 1 Tf
-0.00011 Tc 0 -2.1006 TD
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 61.3333 646.1553 Tm
[(1.)-500 (W)80 (olfe F)80 (, Smythe HA, )37 (Y)111 (unus MB, et al. )18 (The )55 (American College of)]TJ
1.25 -1.25 Td
(Rheumatology 1990 Criteria for the classification of fibromyalgia.)Tj
0 -1.25 TD
[(Report of the Multicenter Criteria Committee. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1990;33:160-72.)Tj
-0.00011 Tc 0.02499 Tw -1.25 -1.25 Td
[(2.)-500 (Maes M, Libbrecht I, )18 (V)111 (an Hunsel F)80 (, et al. )18 (The immune-)]TJ
0 Tc 1.25 -1.25 Td
(inflammatory pathophysiology of fibromyalgia: increased serum)Tj
T*
(soluble gp130, the common signal transducer protein of various)Tj
T*
(neurotrophic cytokines. Psychoneuroendocrinology 1999;24:371-83.)Tj
-0.00011 Tc -1.25 -1.25 Td
[(3.)-500 (Granges G, Zilko P)111 (, Littlejohn GO. Fibromyalgia syndrome: assess-)]TJ
0 Tc 1.25 -1.25 Td
(ment of the severity of the condition 2 years after diagnosis. )Tj
T*
(J Rheumatol 1994;21:523-9.)Tj
-1.25 -1.25 Td
[(4.)-500 (Schochat )18 (T)74 (, Croft P)111 (, Raspe H. )18 (The epidemiology of fibromyalgia. Br)]TJ
1.25 -1.25 Td
(J Rheumatol 1994;33:783-6.)Tj
-1.25 -1.25 Td
[(5.)-500 (Moldofsky H. Sleep, neuroimmune and neuroendocrine functions in)]TJ
1.25 -1.25 Td
[(fibromyalgia and chronic fatique syndrome. )55 (Adv Neuroimmunol)]TJ
0 Tw T*
(1995;5:39-56.)Tj
0.02499 Tw -1.25 -1.25 Td
[(6.)-500 (Caro XJ. Is there an immunologic component to the fibrositis)]TJ
1.25 -1.25 Td
[(syndrome? Rheum Dis Clin North )55 (Am 1989;15:169-86.)]TJ
-1.25 -1.25 Td
[(7.)-500 (Littlejohn GO, )18 (W)80 (einstein C, Helme RD. Increased neurogenic)]TJ
1.25 -1.25 Td
(inflammation in fibrositis syndrome. J Rheumatol 1987;14:1022-5.)Tj
-1.25 -1.25 Td
[(8.)-500 (Bonaccorso S, Lin )55 (AH, )18 (V)111 (erkerk R, et al. Immune markers in)]TJ
1.25 -1.25 Td
(fibromyalgia: comparison with major depressed patients and normal)Tj
-0.00011 Tc T*
[(volunteers. J )55 (Af)18 (fect Disord 1998;48:75-82.)]TJ
0 Tc -1.25 -1.25 Td
[(9.)-500 (Oka )18 (T)74 (, )55 (Auo S, Hori )18 (T)74 (. Intracerebroventricular injection of)]TJ
1.25 -1.25 Td
(interleukin 1beta enhances nociceptive neuronal responses of the)Tj
T*
(trigeminal nucleus caudalis in rats. Brain Res 1994:656:236-44.)Tj
-1.75 -1.25 Td
[(10.)-500 (W)80 (atkins LR, )18 (W)40 (iertelak EP)111 (, Goehler LE, et al. Characterization of)]TJ
1.75 -1.25 Td
(cytokine-induced hyperalgesia. Brain Res 1994;654:15-26.)Tj
-1.7131 -1.25 Td
[(1)37 (1.)-500 (Oka )18 (T)74 (, Oka K, Hosoi M, Hori )18 (T)74 (. Intracerebroventricular injection of)]TJ
1.7131 -1.25 Td
(interleukin-6 induces thermal hyperalgesia in rats. Brain Res)Tj
0 Tw T*
(1995;692:123-8.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(12.)-500 (Deleo JA, Colburn R)55 (W)92 (, Nichols M, Malhotra )55 (A. Interleukin-6)]TJ
0 Tc 1.75 -1.25 Td
(mediated hyperalgesia/allodynia and increased spinal IL-6)Tj
T*
(expression in a rat mononeuropathy model. J Interferon Cytokine)Tj
T*
(Res 1996;16:695-700.)Tj
-1.75 -1.25 Td
[(13.)-500 (Bluthe RM, Crestani F)80 (, Kelley KW)92 (, Dantzer R. Mechanisms of the)]TJ
1.75 -1.25 Td
[(behavioral ef)18 (fects of interleukin1. )55 (Ann New )37 (Y)100 (ork )55 (Acad Sci)]TJ
0 Tw T*
(1992:650:268-75.)Tj
-0.00011 Tc 0.02499 Tw -1.75 -1.25 Td
[(14.)-500 (Spatth SE, Hansen K, Schmidt F)80 (, et al. )55 (Acute ef)18 (fects of recombinant)]TJ
0 Tc 1.75 -1.25 Td
(human interleukin 6 on endocrine and central nervous sleep)Tj
T*
(functions in healthy men. J Clin Endocrinol Metab 1998;83: 1573-9.)Tj
-1.75 -1.25 Td
[(15.)-500 (Maes M. )18 (The immunepathophysiology of major depression. In:)]TJ
-0.00011 Tc 1.75 -1.25 Td
[(Honig )55 (A, van Praag HM, editors. Depression, neurobiological,)]TJ
0 Tc T*
[(psychopathological and therapeutic advances. Chichester: )18 (W)40 (iley;)]TJ
0 Tw T*
(1997:197-215.)Tj
0.0249 Tw 31.25 63.5468 Td
[(16.)-500 (Caro XJ, )18 (W)80 (olfe F)80 (, Johnston )18 (WH. )55 (A)-220 (controlled and blinded study of)]TJ
1.75 -1.25 Td
(immunoreactant deposition at the dermal-epidermal junction of)Tj
T*
(patients with primary fibrositis syndrome. J Rheumatol)Tj
0 Tw T*
(1986;13:1086-92.)Tj
0.0249 Tw -1.75 -1.25 Td
[(17.)-500 (W)80 (allace DJ, Bowman RL, )18 (W)80 (ormsley SB, Peter JB. Cytokines and)]TJ
1.75 -1.25 Td
[(immune regulation in patients with fibrositis. )55 (Arthritis Rheum)]TJ
0 Tw T*
(1989;32:1334-5.)Tj
0.0249 Tw -1.75 -1.25 Td
[(18.)-500 (W)80 (allace DJ, Mar)18 (golin K. )55 (Acute onset fibromyalgia as a complication)]TJ
-0.00011 Tc 1.75 -1.25 Td
[(of interleukin- 2 therapy [abstract]. )55 (Arthritis Rheum 1988;31)]TJ
0 Tc 0 Tw T*
(Suppl:24.)Tj
0.0249 Tw -1.75 -1.25 Td
[(19.)-500 (Hader N, Rimon D, Kinarty )55 (A, Lahat N. )55 (Altered interleukin-2)]TJ
1.75 -1.25 Td
[(secretion in patients with primary fibromyalgia syndrome. )55 (Arthritis)]TJ
T*
(Rheum 1991;34:866-72.)Tj
-1.75 -1.25 Td
[(20.)-500 (Peter JB, )18 (W)80 (allace DJ. )55 (Abnormal immune regulation in fibromyalgia)]TJ
1.75 -1.25 Td
[([abstract]. )55 (Arthritis Rheum 1988;31 Suppl:24.)]TJ
-1.75 -1.25 Td
[(21.)-500 (Caro XJ. Is there an immunologic component to the fibrositis)]TJ
1.75 -1.25 Td
[(syndrome? Rheum Dis Clin North )55 (Am 1989;15:169-86.)]TJ
-1.75 -1.25 Td
[(22.)-500 (Reif)18 (fenber)18 (ger DH, )55 (Amundson L. Fibromyalgia syndrome: a review)65 (.)]TJ
1.75 -1.25 Td
(Am Fam Phys 1996:53:1698-704.)Tj
-1.75 -1.25 Td
[(23.)-500 (Bengtson )55 (A, Ernerudh J, )18 (V)60 (rethem M, et al. )55 (Absence of)]TJ
1.75 -1.25 Td
(autoantibodies in primary fibromyalgia. J Rheumatol 1990;17:)Tj
0 Tw T*
(1682-3.)Tj
0.0249 Tw -1.75 -1.25 Td
[(24.)-500 (W)80 (allace DJ, Peter JB, Bowman RL, )18 (W)80 (ormsley SB, Silverman S.)]TJ
1.75 -1.25 Td
(Fibromyalgia, cytokines, fatigue syndromes, and immune regulation.)Tj
T*
[(In: Fricton JR, )55 (A)92 (wad E, editors. )55 (Advances in pain research and)]TJ
T*
[(therapy)65 (. New )37 (Y)100 (ork:Raven Press; 1990;17:277-87.)]TJ
-1.75 -1.25 Td
[(25.)-500 (Romano )18 (TJ. Fibromyalgia in children: diagnosis and treatment. )18 (W)80 (est)]TJ
1.75 -1.25 Td
[(V)60 (ir)18 (ginia Med J 1991;87:1)37 (12-4.)]TJ
-1.75 -1.25 Td
[(26.)-500 (Buchwald D, Pascualy R, Bombardier C, Kith P)111 (. Sleep disorders in)]TJ
1.75 -1.25 Td
(patients with chronic fatigue. Clin Infect Dis 1994; 88:68-72.)Tj
-1.75 -1.25 Td
[(27.)-500 (Krueger JM, Obal F)80 (. )55 (A)-220 (neuronal group theory of sleep functions. )]TJ
1.75 -1.25 Td
(J Sleep Res 1993;2:63-9.)Tj
-1.75 -1.25 Td
[(28.)-500 (Nazaraki M, )37 (Y)100 (asukawa K, Saito )18 (T)74 (, et al. Soluble forms of the)]TJ
1.75 -1.25 Td
(interleukin-6 signal-transducing receptor component gp130 in)Tj
T*
(human serum possessing a potential to inhibit signals through)Tj
T*
[(membrane-anchored gp130. Blood 1993;82:1)37 (120-6.)]TJ
-0.00011 Tc 0.00729 Tw -1.75 -1.25 Td
[(29.)-500 (Murakami-Mori )-18 (K, T)70 (aga T)74 (, )-18 (Kishimoto T)74 (, )-18 (Nakamura )-18 (S. The )-18 (soluble)]TJ
0.02499 Tw 1.75 -1.25 Td
(form of the IL-6 receptor \(sIL-6R)Tj
/T1_0 1 Tf
0 Tc 0 Tw [0.3 (\002)]TJ
/TT0 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (\) is a potent growth factor for)]TJ
T*
[(AIDS-associated Kaposi\222)55 (s sarcoma \(KS\) cells; the soluble form of)]TJ
0 Tc T*
[(gp130 is antagonistic for IL-6R-induced )55 (AIDS-KS cell growth. Int)]TJ
T*
(Immunol 1996;8:595-602.)Tj
-0.00011 Tc -1.75 -1.25 Td
[(30.)-500 (Matsuda )18 (T)74 (, Fukada )18 (T)74 (, )18 (T)70 (akahashi-T)70 (ezuka M, et al. )55 (Activation of Fes)]TJ
0 Tc 1.75 -1.25 Td
(tyrosine kinase by gp130, an interleukin-6 family cytokine signal)Tj
T*
[(transducer)40 (, and their association. J Biol Chem 1995;12:1)37 (1037-9.)]TJ
-1.75 -1.25 Td
[(31.)-500 (V)111 (anderhaeghe L. Stress, aging and cortisol. )18 (T)70 (otal Health)]TJ
0 Tw 1.75 -1.25 Td
(2001;23:34-5.)Tj
0.02499 Tw -1.75 -1.25 Td
[(32.)-500 (V)111 (anderhaeghe L. Rev up your immune system to prevent disease.)]TJ
1.75 -1.25 Td
[(T)70 (otal Health 1999;21:30-1.)]TJ
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(G\374r)111 (, et al: Cytokines and depr)37 (ession in FM)]TJ
0 Tw 61.4375 -0.0313 Td
(361)Tj
ET
0 0 0 0 scn
/GS0 gs
101.7 58.08 407.5 -10.83 re
f*
0.5 w
101.7 58.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_1 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_2 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
11 0 obj
<>
endobj
87 0 obj
<>
endobj
129 0 obj
<>
endobj
43 0 obj
<>
endobj
52 0 obj
<>
endobj
38 0 obj
<>
endobj
40 0 obj
<>
endobj
72 0 obj
<>stream
HV p}3@a-lX"n".^@ˈd
Jec"X 3"Ė&EP.bPlvf%.*}=j`܋9k}E@ұ%%ԕ]R=_?cau /?Obxua[@\^Q(~h30=kUP}HQ_prIo9. o6{ѕUQ.ZlZp?|W͞7ߺI
n[_5_w0 J|EVJ%q*BZBuֿT}+Z'aq&
,mp$6bn#%.p1ڥËu\<돗
8 (YoDOqXk;oa.Z-1jJzWI@0ϝD,b)"X4+vHo媎7a$|]@fqFLzckd1 8| w$cu6[MA{JhHCQ;3~8v E$T)U\2eu ydu"ɘ w^?H]Ee|N^U%jd%d_2l[Kf۰GXh]pHM8'cd4py^R*%ZYE3F{ّyzSɸWڋY;-a[_N,Ќx@"-N6U-EX,jXMg03/}r\$ yJ~#'%JIS!5_-Vwh14FvF{p3?Rhj:trX1VUm-6YLF=`"Yhe+I(A9f6uFFvN,ft'X~=<@H@ssňDQ(|b*rQ!7D
c\Z(7AWMqd uB A}A~(?ISGdHi(J62Z9jeUٮ]94+:@֨3l?h-W+JYkZP{_vig{"LxӱܱQM~7g><*kwj1IkaQ(;ϻNjF$*^úH.:ti5oQ\QXӔ>S [t2ƥӇ#VT2}D,8Y1egzQOgttm-A^[⟩Qp"8Ϝ'MLXܕnՃ}|>(
xR:!8a៓zWvSAN559^"?m&<ʚ/0
S/Ig0\,\)L+fT?;Ωk[`OK[vͬ,335g}X&RueW)FUn0U(`Esw.يF7sb֎uLOwNV)fCM\}yo4W,Όxi[1C]hЖЎdEZ_)B[QerL#%b 6OpR^_&X7l{H :H##jC|Nqd\$C6'm*V3TZU
cT뉨mP_jH:9?Fc
(u74ds#ŏt%ݔUd-8HS9.;V{}?>Np^HLuA−fQz[doc:qc~S_h{-(~[İHt"*QPsW/Uq;pNH4L81VaKW>R $EmAHh%7| JN҄LFﹳL4Kw=w;Ɋ61?VrkuKXcx
ARclǥ#h.wR%tT*B0T